Dasgupta Amitava, Tso Gertie, Wells Alice
Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center at Houston, Houston, Texas 77030, USA.
J Clin Lab Anal. 2008;22(4):295-301. doi: 10.1002/jcla.20252.
Asian ginseng, Siberian ginseng, and Indian Ayurvedic medicine Ashwagandha demonstrated modest interference with serum digoxin measurements by the fluorescent polarization immunoassay (FPIA). Recently, Abbott Laboratories marketed a new digoxin immunoassay, Digoxin III for application on the AxSYM analyzer. We studied potential interference of these herbal supplements on serum digoxin measurement by Digoxin III assay in vitro and compared our results with the values obtained by Tina-quant assay. Aliquots of drug-free serum pool were supplemented with various amounts of Asian ginseng, Siberian ginseng, or Ashwagandha approximating expected concentrations after recommended doses and overdoses of these herbal supplements in serum. Then digoxin concentrations were measured by the Digoxin III and Tina-quant (Roche Diagnostics) assay. We also supplemented aliquots of a digoxin pool prepared from patients receiving digoxin with various amounts of these herbal supplements and then measured digoxin concentrations again using both digoxin immunoassays. We observed modest apparent digoxin concentrations when aliquots of drug-free serum pool were supplemented with all three herbal supplements using Digoxin III assay (apparent digoxin in the range of 0.31-0.57 ng/ml), but no apparent digoxin concentration (except with the highest concentration of Ashwagandha supplement for both brands) was observed using the Tina-quant assay. When aliquots of digoxin pool were further supplemented with these herbal supplements, digoxin concentrations were falsely elevated when measured by the new Digoxin III assay. For example, we observed 48.2% (1.63 ng/ml digoxin) increase in digoxin concentration when an aliquot of Digoxin pool 1 (1.10 ng/ml digoxin) was supplemented with 50 microl of Asian ginseng extract (Brand 2). Measuring free digoxin does not eliminate the modest interferences of these herbal supplements in serum digoxin measurement by the Digoxin III assay.
亚洲人参、西伯利亚人参和印度阿育吠陀医学中的南非醉茄通过荧光偏振免疫分析法(FPIA)对血清地高辛测量显示出适度干扰。最近,雅培实验室推出了一种新的地高辛免疫分析法,即用于AxSYM分析仪的地高辛III。我们在体外研究了这些草药补充剂对采用地高辛III分析法测量血清地高辛的潜在干扰,并将我们的结果与通过 Tina-quant 分析法获得的值进行比较。向无药血清库的等分试样中添加不同量的亚洲人参、西伯利亚人参或南非醉茄,其含量接近这些草药补充剂在推荐剂量和过量服用后血清中的预期浓度。然后通过地高辛III和 Tina-quant(罗氏诊断)分析法测量地高辛浓度。我们还向由接受地高辛治疗的患者制备的地高辛库的等分试样中添加不同量的这些草药补充剂,然后再次使用两种地高辛免疫分析法测量地高辛浓度。当使用地高辛III分析法向无药血清库的等分试样中添加所有三种草药补充剂时,我们观察到适度的表观地高辛浓度(表观地高辛范围为0.31 - 0.57 ng/ml),但使用 Tina-quant 分析法未观察到明显的表观地高辛浓度(两个品牌的南非醉茄补充剂最高浓度除外)。当地高辛库的等分试样进一步添加这些草药补充剂时,通过新的地高辛III分析法测量时地高辛浓度会被错误地升高。例如,当向1号地高辛库(地高辛浓度为1.10 ng/ml)的等分试样中添加50微升亚洲人参提取物(品牌2)时,我们观察到地高辛浓度增加了48.2%(地高辛浓度为1.63 ng/ml)。测量游离地高辛并不能消除这些草药补充剂在通过地高辛III分析法测量血清地高辛时的适度干扰。